- Home
- EVM vs PROK Comparison
EVM vs PROK Comparison
Compare EVM & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVM
- PROK
- Stock Information
- Founded
- EVM 2002
- PROK 2015
- Country
- EVM United States
- PROK United States
- Employees
- EVM N/A
- PROK N/A
- Industry
- EVM Finance/Investors Services
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EVM Finance
- PROK Health Care
- Exchange
- EVM Nasdaq
- PROK Nasdaq
- Market Cap
- EVM 228.0M
- PROK 206.0M
- IPO Year
- EVM N/A
- PROK N/A
- Fundamental
- Price
- EVM $9.36
- PROK $1.50
- Analyst Decision
- EVM
- PROK Buy
- Analyst Count
- EVM 0
- PROK 5
- Target Price
- EVM N/A
- PROK $4.50
- AVG Volume (30 Days)
- EVM 55.8K
- PROK 344.0K
- Earning Date
- EVM 01-01-0001
- PROK 03-21-2025
- Dividend Yield
- EVM 4.01%
- PROK N/A
- EPS Growth
- EVM N/A
- PROK N/A
- EPS
- EVM 0.20
- PROK N/A
- Revenue
- EVM N/A
- PROK N/A
- Revenue This Year
- EVM N/A
- PROK N/A
- Revenue Next Year
- EVM N/A
- PROK N/A
- P/E Ratio
- EVM $47.61
- PROK N/A
- Revenue Growth
- EVM N/A
- PROK N/A
- 52 Week Low
- EVM $7.67
- PROK $1.34
- 52 Week High
- EVM $9.59
- PROK $4.44
- Technical
- Relative Strength Index (RSI)
- EVM 48.24
- PROK 41.47
- Support Level
- EVM $9.28
- PROK $1.50
- Resistance Level
- EVM $9.39
- PROK $1.67
- Average True Range (ATR)
- EVM 0.06
- PROK 0.10
- MACD
- EVM -0.01
- PROK -0.00
- Stochastic Oscillator
- EVM 33.33
- PROK 10.71
About EVM Eaton Vance California Municipal Bond Fund of Beneficial Interest $.01 par value
Eaton Vance California Municipal Bond Fund is an investment company with an objective to provide current income exempt from regular federal income tax, including alternative minimum tax, and, in state specific funds, taxes in its specified state. The company provides its solutions to individual investors, institutional investors, high net worth individuals, family office investors, and financial professionals. It offers a range of equity, income, and alternative strategies to institutional investors, both in the United States and internationally.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease.